APA (7th ed.) Citation

Jacoby, D., Ho, C. Y., Lester, S. J., Wang, A., & Olivotto, I. (2021). Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply. Lancet, 397(10272), 369. https://doi.org/10.1016/S0140-6736(20)32391-6

Chicago Style (17th ed.) Citation

Jacoby, Daniel, Carolyn Y. Ho, Steven J. Lester, Andrew Wang, and Iacopo Olivotto. "Mavacamten for Hypertrophic Obstructive Cardiomyopathy - Authors' Reply." Lancet 397, no. 10272 (2021): 369. https://doi.org/10.1016/S0140-6736(20)32391-6.

MLA (9th ed.) Citation

Jacoby, Daniel, et al. "Mavacamten for Hypertrophic Obstructive Cardiomyopathy - Authors' Reply." Lancet, vol. 397, no. 10272, 2021, p. 369, https://doi.org/10.1016/S0140-6736(20)32391-6.